Literature DB >> 13171379

Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease.

M WEINER, T CHENKIN, J J BURNS.   

Abstract

Entities:  

Keywords:  ANALGESICS/metabolism; LIVER/diseases

Mesh:

Substances:

Year:  1954        PMID: 13171379     DOI: 10.1097/00000441-195407000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  6 in total

1.  [Mechanism of action of butazolidine].

Authors:  H GROS
Journal:  Klin Wochenschr       Date:  1956-05-01

Review 2.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

4.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

5.  Altered elimination of antipyrine in patients with acute viral hepatitis.

Authors:  D A Burnett; A J Barak; D J Tuma; M F Sorrell
Journal:  Gut       Date:  1976-05       Impact factor: 23.059

Review 6.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.